GRTS vs. ATHA, JATT, PLX, ELUT, DTIL, CGTX, ALVR, TIL, PASG, and CVM
Should you be buying Gritstone bio stock or one of its competitors? The main competitors of Gritstone bio include Athira Pharma (ATHA), JATT Acquisition (JATT), Protalix BioTherapeutics (PLX), Elutia (ELUT), Precision BioSciences (DTIL), Cognition Therapeutics (CGTX), AlloVir (ALVR), Instil Bio (TIL), Passage Bio (PASG), and CEL-SCI (CVM). These companies are all part of the "biological products, except diagnostic" industry.
Gritstone bio (NASDAQ:GRTS) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, community ranking, valuation, risk, media sentiment and analyst recommendations.
Gritstone bio currently has a consensus target price of $5.33, indicating a potential upside of 577.33%. Athira Pharma has a consensus target price of $19.00, indicating a potential upside of 653.97%. Given Athira Pharma's higher probable upside, analysts plainly believe Athira Pharma is more favorable than Gritstone bio.
Athira Pharma has lower revenue, but higher earnings than Gritstone bio. Athira Pharma is trading at a lower price-to-earnings ratio than Gritstone bio, indicating that it is currently the more affordable of the two stocks.
In the previous week, Gritstone bio had 3 more articles in the media than Athira Pharma. MarketBeat recorded 14 mentions for Gritstone bio and 11 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 0.50 beat Gritstone bio's score of 0.24 indicating that Athira Pharma is being referred to more favorably in the news media.
48.5% of Gritstone bio shares are owned by institutional investors. Comparatively, 57.1% of Athira Pharma shares are owned by institutional investors. 4.6% of Gritstone bio shares are owned by insiders. Comparatively, 19.8% of Athira Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Gritstone bio received 122 more outperform votes than Athira Pharma when rated by MarketBeat users. Likewise, 69.31% of users gave Gritstone bio an outperform vote while only 58.06% of users gave Athira Pharma an outperform vote.
Gritstone bio has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, Athira Pharma has a beta of 2.83, meaning that its share price is 183% more volatile than the S&P 500.
Athira Pharma has a net margin of 0.00% compared to Gritstone bio's net margin of -926.13%. Athira Pharma's return on equity of -80.59% beat Gritstone bio's return on equity.
Summary
Athira Pharma beats Gritstone bio on 9 of the 16 factors compared between the two stocks.
Get Gritstone bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GRTS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GRTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gritstone bio Competitors List
Related Companies and Tools
